Towards an innovative oral combination treatment for visceral leishmaniasis


Visceral leishmaniasis is a neglected tropical disease and fatal if left untreated in over 95% of cases. Existing therapies have serious drawbacks in terms of safety, drug resistance, field-adapted use, cost, length and tolerability. Drugs for Neglected Disease initiative, a non-profit drug research and development organization, carries out preclinical activities on two drug compounds for the development of an oral combination therapy for this disease that mainly affects the poor.

Región/País Tema Período Presupuesto
A nivel mundial
Salud
Enfermedad infecciosa
Servicios médicos
01.11.2017 - 31.12.2018
CHF 500'000
Contexto Visceral leishmaniasis is a neglected tropical disease and fatal if left untreated in over 95% of cases. Existing therapies have serious drawbacks in terms of safety, drug resistance, field-adapted use, cost, length and tolerability. Drugs for Neglected Disease initiative, a non-profit drug research and development organization, carries out preclinical activities on two drug compounds for the development The overall goal of this project is to contribute to the reduction of the burden of visceral leishmaniasis, one of the most neglected tropical diseases. The preclinical activities targeted with this project will allow preparing the first in-human study of two promising preclinical candidates. If successful, this will ultimately improve therapeutic possibilities for patients affected by visceral leishmaniasis who often are poor people and will help improve their health outcomes
Objetivos The overall goal of this project is to contribute to the reduction of the burden of visceral leishmaniasis, one of the most neglected tropical diseases. The preclinical activities targeted with this project will allow preparing the first in-human study of two promising preclinical candidates. If successful, this will ultimately improve therapeutic possibilities for patients affected by visceral leishmaniasis who often are poor people and will help improve their health outcomes.
Grupos destinarios The main direct beneficiaries of the project are mainly the poor people affected by or exposed to visceral leishmaniasis in more than 80 countries worldwide and for whom visceral leishmaniasis is potentially fatal if untreated.
Efectos a medio plazo This single phase contributes to the development of a patient-adapted, simple oral therapy for visceral leishmaniasis that is affordable, safe and efficacious in both children and adults.
Resultados

Resultados previstos:  

The key outputs of the single phase are the following preclinical activities: 

  • Manufacturing of clinical supplies for the first in-human study by the end of 2017.
  • Preparatory activities for the first in -human study for two preclinical candidates.


Resultados de las fases anteriores:   Not applicable (single phase)


Dirección / Officina Federal responsable COSUDE
Crédito Cooperación al desarrollo
Contrapartes del proyecto Contraparte del contrato
Organización suiza sin fines de lucro
  • Otra organización suiza sin fines lucrativos


Coordinación con otros proyectos y actores Product Development Partnerships (PDPs) in Geneva supported by SDC: Medicines for Malaria Venture (MMV), Foundation for Innovative New Diagnostics (FIND), as well as the Special Programme for Research and Training in Tropical Diseases (TDR) of the World Health Organization (WHO).
Presupuesto Fase en curso Presupuesto suizo CHF   500'000 Presupuesto actual suizo ya emitido CHF   500'000